๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Cliramitug clinical trials

Also listed in trial records as ALXN2220, NI006
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 4 trials in our Germany, France, Spain, UK, USA, China, Italy, Netherlands, Sweden, Canada, Japan, Ireland, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Turkey, Brazil, South Korea, Taiwan, Australia and Israel registers that name Cliramitug as an intervention. Synced 1 Oct 2026
4Current trials
0Recruiting now
3Lead sponsors
25Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards
At a glance

Cliramitug is named as an intervention in 4 current clinical trials in our Germany, France, Spain, UK, USA, China, Italy, Netherlands, Sweden, Canada, Japan, Ireland, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Turkey, Brazil, South Korea, Taiwan, Australia and Israel registers. None are recruiting at the moment. The most common phase is Phase 3. The sponsor with the most trials is Alexion Pharmaceuticals, Inc (2). The most-studied condition is Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

Trials by status

  • Not yet open125%
  • Active, closed375%

Trials by phase

  • Phase 3250%
  • Phase 2250%
01

Clinical trials of Cliramitug

4 trials
StudyPhaseStatusLead sponsorRegisters
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483 · ClinicalTrials.gov ↗ · Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Phase 3 Not yet open Alexion Pharmaceuticals, Inc Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931 · ClinicalTrials.gov ↗ · Transthyretin Amyloid Cardiomyopathy
Phase 3 Active, closed Alexion Pharmaceuticals, Inc Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM
NCT07213583 · ClinicalTrials.gov ↗ · Amyloid Transthyretin Cardiomyopathy
Phase 2 Active, closed Neurimmune AG Germany, France, Spain, Netherlands
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354 · ClinicalTrials.gov ↗ · Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Phase 2 Active, closed AstraZeneca UK, USA, China, Germany, France, Spain, Italy, Sweden, Canada, Japan

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Cliramitug

3 conditions
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)2Transthyretin Amyloid Cardiomyopathy1Amyloid Transthyretin Cardiomyopathy1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Alexion Pharmaceuticals, Inc2
AstraZeneca1
Neurimmune AG1
04

By country register

RegisterTrialsRecruiting
Clinical trials in Germany40
Clinical trials in France40
Clinical trials in Spain40
Clinical trials in UK30
Clinical trials in USA30
Clinical trials in China30
Clinical trials in Italy30
Clinical trials in Netherlands30
Clinical trials in Sweden30
Clinical trials in Canada30
Clinical trials in Japan30
Clinical trials in Ireland20
Clinical trials in Belgium20
Clinical trials in Denmark20
Clinical trials in Poland20
Clinical trials in Switzerland20
Clinical trials in Austria20
Clinical trials in Czechia20
Clinical trials in Norway20
Clinical trials in Turkey20
Clinical trials in Brazil20
Clinical trials in South Korea20
Clinical trials in Taiwan20
Clinical trials in Australia20
Clinical trials in Israel20

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about Cliramitug trials

How many clinical trials are testing Cliramitug?

4 current trials in our Germany, France, Spain, UK, USA, China, Italy, Netherlands, Sweden, Canada, Japan, Ireland, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Turkey, Brazil, South Korea, Taiwan, Australia and Israel registers name Cliramitug (also registered as ALXN2220) as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.

Are Cliramitug trials recruiting patients?

Not at the moment. None of the 4 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Who sponsors Cliramitug clinical trials?

Alexion Pharmaceuticals, Inc (2), AstraZeneca (1) and Neurimmune AG (1). The number in brackets is how many trials each organisation leads.

Are there Cliramitug clinical trials in Ireland?

Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cliramitug works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Cliramitug works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cliramitug (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.